High expression of ASPM may be significantly associated with poor prognosis in lung cancer patients, and at the same time, a targeted therapeutic strategy against ASPM is expected to lead to the development of new effective drugs, provide more precise treatment options for lung cancer patients, inhibit tumor proliferation and invasion, prolong patient survival time and improve quality of life. This evidence concerns the gene ASPM and lung cancer.